Viking Therapeutics, Inc. (VKTX)

In February 2026, the company reported its fourth-quarter and year-end 2025 financial results, outlining plans to advance the oral formulation of VK2735 into Phase 3 development for obesity in Q3 2026. In March 2026, Viking Therapeutics announced the completion of enrollment in its Phase 3 VANQUISH-2 trial of VK2735 and a maintenance dosing study, with results expected in Q3 2026. The stock has experienced fluctuations influenced by market trends and positive company-specific catalysts, including advancing Phase 3 obesity trials and analyst commentary, with some investors referring to VK2735 as a potential "Ozempic killer."

As a clinical-stage biopharmaceutical company, Viking Therapeutics, Inc. does not currently have commercialized products or services that would exhibit traditional demand seasonality. The company's focus is on research and development, with its product candidates still undergoing clinical trials. However, there is some indication of seasonality in the stock's performance, with historical data suggesting a chance of a "red month" for March based on past trends.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders within the Healthcare sector, specifically in the Biotechnology industry. Key product candidates include VK2809 for lipid and metabolic disorders, VK0214 for X-linked adrenoleukodystrophy, VK2735 for metabolic disorders like obesity and type 2 diabetes, and VK5211.

Viking Therapeutics, Inc. is headquartered in San Diego, California, United States, with primary operations based in the United States, and its biopharmaceutical development work has a global impact.

Viking Therapeutics generally holds a positive brand reputation, particularly within the investment community, driven by the promising developments in its clinical pipeline. The company has received a "Moderate Buy" consensus rating from analysts, with optimism about its future prospects. The advancement of its VK2735 program has generated considerable excitement, with some investors viewing it as a strong competitor to existing market leaders.

Viking Therapeutics, Inc. has a diverse ownership structure, with institutional shareholders holding approximately 62.25% to 76.03% of the stock, including major holders like Vanguard Group Inc. and BlackRock Inc. Insiders own about 4.10% to 8.90% of the company's stock, with Ligand Pharmaceuticals Inc. being the largest individual shareholder. Retail investors account for approximately 28.85% to 58.72% of the ownership.